Atricure, Inc. (ATRC) Files Form 4 Insider Selling : Elizabeth D Krell Sells 6,000 Shares

Atricure, Inc. (ATRC): Elizabeth D Krell , director of Atricure, Inc. sold 6,000 shares on Sep 13, 2016. The Insider selling transaction was reported by the company on Sep 14, 2016 to the Securities and Exchange Commission. The shares were sold at $15.93 per share for a total value of $95,580.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 18, 2016, Elizabeth D Krell (director) sold 5,000 shares at $15.20 per share price.On Dec 7, 2015, Douglas J Seith (Chief Operating Officer) sold 5,000 shares at $21.55 per share price.Also, On May 8, 2015, Karen P Robards (director) sold 2,650 shares at $22.18 per share price.On Apr 1, 2015, Michael D Hooven (director) sold 142,268 shares at $20.67 per share price.

AtriCure: On Monday, Sep 12, 2016 heightened volatility was witnessed in AtriCure which led to swings in the share price. The shares opened for trading at $16.08 and hit $16.53 on the upside , eventually ending the session at $16.51, with a gain of 2.36% or 0.38 points. The heightened volatility saw the trading volume jump to 199,965 shares. The 52-week high of the share price is $26.88 and the company has a market cap of $548 M . The 52-week low of the share price is at $13.44.

AtriCure Money Flow Index Chart

Company has been under the radar of several Street Analysts.AtriCure is Resumed by JMP Securities to Mkt Outperform. The Rating was issued on Jun 30, 2016.

AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.

Leave a Reply

AtriCure - Is it time to Sell?

Top Brokerage Firms are advising their investors on AtriCure. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.